Nueva Publicación de nuestra investigadora

 Claudia Lizette Banda Flores

Revista: Mycoses                SJR: 1.02 Q: 1

Current situation of endemic mycosis in the Americas and the Caribbean: Proceedings of the first international meeting on endemic mycoses of the Americas (IMEMA)


  • 1Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
  • 2Center of Expertise in Mycology Radboudumc/CWZ, Nijmegen, The Netherlands.
  • 3Studies in Translational Microbiology and Emerging Diseases (MICROS) Research Group, School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia.
  • 4Medical Mycology Group, School of Medicine, Microbiology and Parasitology Department, Universidad de Antioquia, Medellín, Antioquia, Colombia.
  • 5Hospital General de Mexico Dr Eduardo Liceaga, Ciudad de Mexico, Mexico.
  • 6Centre d'Investigation Clinique Antilles Guyane Inserm 1424, Cayenne, France.
  • 7Centre Hospitalier de Cayenne, Cayenne, France.
  • 8Universidad Peruana Cayetano Heredia (UPCH), Hospital Cayetano Heredia, Lima, Peru.
  • 9Departamento de Micología, Instituto Nacional de Enfermedades Infecciosas (INEI), Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) "Dr. Carlos G. Malbrán", Buenos Aires, Argentina.
  • 10Department of Infectious Diseases and Infection Control, Universidade Federal do Maranhão, UFMA, São Luís, Maranhão, Brazil.
  • 11Instituto D'Or de Pesquisa e Ensino, IDOR, Hospital UDI, São Luis, Maranhão, Brazil.
  • 12Asociación de Salud Integral, Guatemala City, Guatemala.
  • 13Centro Nacional de Enfermedades Tropicales (CENETROP), Santa Cruz, Bolivia.
  • 14Department of Public Health, Federal University of Paraná, Brazil.
  • 15Department of Medicine, Division of Infectious Diseases, University of Alberta, Edmonton, Alberta, Canada.
  • 16Facultad de Medicina, Pontificia Universidad Católica del Ecuador, Quito, Ecuador.
  • 17Unidad de Investigaciones en Biomedicina, Zurita & Zurita Laboratorios, Quito, Ecuador.
  • 18Faculdade de Medicina, Universidade Federal do Ceará, Fortaleza, CE, Brazil.
  • 19Hospital São José de Doenças Infecciosas, Secretaria de Saúde, Ceará, Brazil.
  • 20Sociedad Venezolana de Microbiología, Caracas, Venezuela.
  • 21Sección Micologia, Division Infectología, Hospital de Clinicas "José de San Martín" Universidad de Buenos Aires, Buenos Aires, Argentina.
  • 22Departamento de Bacteriología y Micología, Laboratorio Central de Salud Pública, Ministerio de Salud Pública y Bienestar Social, Asunción, Paraguay.
  • 23Departamento de Enfermedades Infecciosas del Adulto, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
  • 24Instituto de Medicina Regional, Universidad Nacional del Nordeste, Consejo Nacional de Investigaciones Científicas y Técnicas de Argentina (CONICET), Resistencia, Chaco, Argentina.

PMID: 35971917                                     DOI: 10.1111/myc.13510


Background: The Americas are home to biologically and clinically diverse endemic fungi, including Blastomyces, Coccidioides, Emergomyces, Histoplasma, Paracoccidioides and Sporothrix. In endemic areas with high risk of infection, these fungal pathogens represent an important public health problem.

Objectives: This report aims to summarise the main findings of the regional analysis carried out on the status of the endemic mycoses of the Americas, done at the first International Meeting on Endemic Mycoses of the Americas (IMEMA).

Methods: A regional analysis for the Americas was done, the 27 territories were grouped into nine regions. A SWOT analysis was done.

Results: All territories reported availability of microscopy. Seventy percent of territories reported antibody testing, 67% of territories reported availability of Histoplasma antigen testing. None of the territories reported the use of (1-3)-β-d-glucan. Fifty two percent of territories reported the availability of PCR testing in reference centres (mostly for histoplasmosis). Most of the territories reported access to medications such as trimethoprim-sulfamethoxazole, itraconazole, voriconazole and amphotericin B (AMB) deoxycholate. Many countries had limited access to liposomal formulation of AMB and newer azoles, such as posaconazole and isavuconazole. Surveillance of these fungal diseases was minimal.

Conclusions: A consensus emerged among meeting participants, this group concluded that endemic mycoses are neglected diseases, and due to their severity and lack of resources, the improvement of diagnosis, treatment and surveillance is needed.

Keywords: blastomyces; coccidioides; histoplasma; paracoccidioides.

© 2022 The Authors. Mycoses published by Wiley-VCH GmbH.

Artículo Completo 


Conoce las publicaciones por año de nuestros investigadores 

Visualiza el resumen de nuestra oficina de investigación con las  publicaciones recientes 

Oficina de investigación - ¿En qué te podemos ayudar?